MetaCap

Assembly Biosciences (ASMB) vs Monopar Therapeutics (MNPR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Monopar Therapeutics (MNPR) has outperformed Assembly Biosciences (ASMB) over the past year, losing 24.6% versus a loss of 42.4%. Over five years, MNPR leads with a +184.5% price change compared with -21.3% for ASMB. Monopar Therapeutics is the larger company by market cap ($467.6 million vs $454.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASMB-42.36%MNPR-24.64%
+39%-7%-54%
Nov 21, 20251 yearNov 20, 2026
ASMB-19.60%MNPR+192.99%
+431%+156%-119%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASMB versus MNPR key metrics
MetricASMBMNPR
Share price$22.19$69.00
Market cap$454.39M$467.60M
1-day change-1.38%-1.84%
YTD return-34.75%+5.67%
1-year return-42.36%-24.64%
5-year return-21.31%+184.54%
P/E ratio (TTM)29.59—
EPS (TTM)$0.75$-2.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.30M$0
Revenue growth (YoY)+153.52%—
Net income (latest FY)$-6.12M$-13.72M
Operating margin-16.76%—
Net margin-8.47%—
52-week high$39.65$124.82
52-week low$19.20$50.07
Distance from 52-week high-44.04%-44.72%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+130.73%+88.65%
Average volume309.38K151.83K
Shares outstanding20.48M6.78M
Employees7322
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MNPR has outperformed ASMB by 17.7 percentage points over the past year.

About Assembly Biosciences

ASMB stock →

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About Monopar Therapeutics

MNPR stock →

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.

Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees

ASMB vs MNPR FAQ

Which is bigger, Assembly Biosciences or Monopar Therapeutics?

Monopar Therapeutics (MNPR) is larger, with a market capitalization of $467.60M compared with $454.39M for Assembly Biosciences (ASMB).

Which stock has performed better over the past year, ASMB or MNPR?

MNPR returned -24.64% over the past 12 months, compared with -42.36% for ASMB (price return, excluding dividends). Past performance does not predict future results.

Are Assembly Biosciences and Monopar Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons